AzTrials
AzTrials

Postoperative PainPhase 4NCT04459026

Comparison of Administation Routes of Ropivacaine

A Phase 4 study testing combination, infiltration and instillation in people with Postoperative Pain, run by Universiteit Antwerpen at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to evaluate the effect of different routes of local anaesthesia administration in laparoscopic procedures to reduce post-operative pain (intra-peritoneal infusion of Ropivacaine 0.75%, port site injection of Ropivacaine 0.75% or a combination of both techniques), through a randomized… Read more about this study

Who is it for?
Ages 18 to 70 years, women onlyHealthy volunteers can take part
Conditions the study is for
Postoperative Pain
What is being tested?
combination, infiltration and instillation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
60 participants
Where
1 siteBelgium
Study dates
1 Jul 2017to 29 Feb 2020
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • Women only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Elective gynecologic laparoscopy for benign conditions at Antwerp University Hospital.
  • Successful laparoscopy without surgical or anesthetic complications.
  • Female
  • 18-70 years
  • ASA I-II

Who cannot join

  • Hypersensitivity to anaesthetics of the amide-type
  • Obesity, BMI > 35
  • Patients with chronic use of analgesics / chronic pain
  • Patients with an abnormal liver function
  • Urgent surgical procedures
  • Pregnancy (this means we only include patients who use contraceptives, are sterilized, have a negative dipstick testing or a negative serum testing or patients who are postmenopausal)

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • UZA

    Edegem, Antwerp, 2650

Other trials in Belgium

About this study

Official title: Comparative Study Between Different Routes of Ropivacaïne Administration to Reduce Post-operative Pain in Gynecological Laparoscopy, a Double Blind Randomized Trial.

The purpose of this study is to evaluate the effect of different routes of local anaesthesia administration in laparoscopic procedures to reduce post-operative pain (intra-peritoneal infusion of Ropivacaine 0.75%, port site injection of Ropivacaine 0.75% or a combination of both techniques), through a randomized one-center double-blinded study.

Read the detailed description

Research Question What is the best route of Ropivacaine administration in laparoscopic procedures in decreasing post-operative pain? Is it port site injection, intra-peritoneal instillation of local anesthetics or is it a combination of both routes? Our hypothesis is that a combination of port site injection and intra-peritoneal instillation of local anesthetics will be more effective in lowering pain the first 24 hours after surgery.

  1. Characteristics of the patient population Inclusion criteria
  2. Elective gynecologic laparoscopy for benign conditions at Antwerp University Hospital.
  3. Successful laparoscopy without surgical or anesthetic complications.
  4. Female
  5. 18-70 years
  6. ASA( American Society of Anesthesia) I-II Exclusion criteria (1) Hypersensitivity to anaesthetics of the amide-type (2) Obesity, BMI > 35 (3) Patients with chronic use of analgesics / chronic pain (4) Patients with an abnormal liver function (5) Urgent surgical procedures (6) Pregnancy (this means we only include patients who use contraceptives, are sterilized, have a negative dipstick testing or a negative serum testing or patients who are postmenopausal) 4. Characteristics of the treatment We will be using ropivacaine - naropin 7,5mg/ml, a local anaesthetic of the amide type. The administered dose of this local anaesthetic will be 3mg/kg for each patient. Depending on the study group the patient belongs to, this dose will be given in full by either local injection at the trocar entry points or by intraperitoneal injection or it will be divided between both injection sites, respectively 1mg at the trocar sites and 2mg intraperitoneal. The unequal dose distribution is based on the surface area the local anaesthetic has to cover.
  7. Methodology Anaesthetic management will be standardized for each person. The anaesthetist will insert an intravenous line and connect the patient to the monitor. We will be using routine intraoperative monitoring devices such as an electrocardiograph, a pulse oximetry and a non-invasive blood pressure monitor. The patient is preoxygenated with 100% O2 before induction.

Anaesthetic protocol

Induction:

  • fentanyl 2μg/kg
  • Propofol TCI marsh model 6μg/ml - titration based on effect
  • Rocuronium 0.5mg/kg

Maintenance:

  • Propofol TCI Marsh model: 4μ/ml - (8-12mg/kg/u) - titration based on effect, blood pressure and heart rate.

Analgesia intraoperatively:

  • Ketorolac 30mg at induction (if no contraindications; and > 60kg; if the patient weight is < 60kg the dose will be lowered to 20mg)
  • Paracetamol 1g one half hour before the end of the surgery Different study groups

At the end of the successful gynaecologic laparoscopy, patients will receive the additional pain management according to their randomly assigned study group:

  • Group A patients will receive 1) intra-abdominal instillation 0.75% Ropivacaine 2 mg / kg in 200 ml of NaCl through the trocars and 2) Infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 1 mg / kg in 20 ml of NaCl (Sodiumchloride)
  • Group B patients will receive infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 3 mg / kg in 20 ml of NaCl.
  • Group C patients will receive intra-abdominal instillation 0.75% Ropivacaine 3 mg / kg in 200 ml of NaCl through the trocars.

Suction and aspiration is avoided after instillation of local anaesthetic intra-abdominal in group A and C.

The study medication will be prepared in the operating room right before use. This means that neither the anaesthesiologist nor the surgeon, performing the surgery, are blinded. This isn't a problem since it is already at the end of the procedure and they will not be the ones following up on the patients for study purposes.

End of the procedure After surgery, the patients will be transferred to the recovery room. A standard postoperative analgesic regimen will be used in all patients with Numeric Rating Scale (NRS) >= 3.

As long as the patient is in the hospital, she will receive paracetamol 1g every 6 hours, preferably given orally. If, despite this regimen, the NRS score is higher than 3, they will receive tramadol 100mg IV + alizapride 50 mg. There will be a re-evaluation after 30 minutes. If the NRS is still higher than 3, an anaesthesiologist will be consulted and a subcutaneous dose of morphine will be given. The dose will be 5 mg if the body weight of the patient is less than 90 kg and the patient is less than 70 years old. In a patient heavier than 90 kg and younger than 70 years, the dose will be 10mg morphine subcutaneously.

The nurses of the day hospital will complete the first page(s) of the patient's questionnaire.

Later that day the patient will be discharged from the hospital if all the discharge criteria are met according to standard operating procedures.

When going home all patients receive a map with their questionnaire, a prescription for paracetamol 1g if necessary, max 4 times a day, and a last reminder to not forget about the questionnaire. In this study, we will focus about the first week postoperatively.

  1. Questionnaire In total 7 parameters will be questioned: abdominal pain, shoulder pain, nausea, vomiting, itching, urinating and activity level. The questionnaire that will be given to the patients consists of an introduction page and 5 identical questionnaires. Assessment will take place at respectively 1 h, 2 h, 6 h, 24 h and 1 w postoperatively. Abdominal pain will be scored by the patients using the numeric rating scale. The patients will be asked to rate the severity of pain via NRS ranging from no pain (score 0) to the worst possible pain (score 10).

This method is explained in the introduction page and is the method of choice to evaluate pain in the recovery room. This means that all the patients will already be familiar with the scoring system before going home. Intra-abdominal pain will be assessed during rest and during an effort, for example coughing. In the postoperative period, the time to first analgesic administration and total analgesic requirements (paracetamol, tramadol and morphine) will be recorded.

For the other parameters, our interests lie in the presence or absence of these elements so we chose for a simple "yes" or "no" question.

The individuals filling in the questionnaires, the patients or the nurses of the recovery room will always be blinded to the study groups, as will the nurse contacting the patients for the follow up. The research nurses will contact the patients through telephone 24 h after surgery and again 1 week after surgery to get the answers of the questionnaires. They will be unaware of the study group the patient was subdivided into. The responses will be recorded and analysed by members of the research group. If the patients are not pain free after one week, we will contact them again after one month. After that, they will be called once a month until they are pain free or 6 months have passed. Postoperative pain lasting more than one week could be and indicator for the onset of chronic pain. (13) However, this topic will need additional research that, for the moment, is beyond the scope of our investigation.

  1. Statistics: Comparison of the categorical or ordinal variables will be performed using Chi square or Fisher exact test and relative risk with 95 % confidence intervals as appropriate Continuous variables will be presented in median values and will be compared using ANOVA. Multivariate logistic regression analysis will be performed. P values of less than 0.05 will be regarded statistically significant. All the calculations will be performed with the SPSS 11.0 statistical package (SPSS, Inc., Chicago, IL) (Dupont WD, Plummer WD, http://www.spss.com). According to that the sample size should be at least 16 cases for each group when we want the power of the study to be 80%.æ
Being tested
combination, infiltration, instillation
Keywords
ropivacaine, laparoscopy
Medical subject headings
Pain, Postoperative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • combinationProcedure or surgery

    Also called ropivacaine intraperitoneal and local

    instillation and infiltration of ropivacaine

  • infiltrationProcedure or surgery

    Also called ropivacaine local

    local infiltration ropivacaine

  • instillationProcedure or surgery

    Also called intraperitoneal ropivacaine

    intraperitoneal ropivacaine instillation

Study groups in NCT04459026
Study groupRoleWhat they receive
group A - combinationExperimentalGroup A patients will receive intra-abdominal instillation 0.75% Ropivacaine 2 mg / kg in 200 ml of NaCl through the trocars and 2) Infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 1 mg / kg in 20 ml of NaCl
Receives: Procedure: combination
Group B - infiltrationExperimentalGroup B patients will receive infiltration of the surgical wounds at the trocar sites with 0.75% Ropivacaine 3 mg / kg in 20 ml of NaCl.
Receives: Procedure: infiltration
Group C - instillationActive comparatorGroup C patients will receive intra-abdominal instillation 0.75% Ropivacaine 3 mg / kg in 200 ml of NaCl through the trocars.
Receives: Procedure: instillation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Abdominale Pain scores postoperatively

    Numeric rating scale NRS

    Measured: one week

  2. need of pain medication postoperatively

    note in file

    Measured: one week

Secondary outcomes (5)
  1. postoperative nausea and vomiting

    score yes/no

    Measured: one week

  2. shoulder pain postoperatively

    score yes/no

    Measured: one week

  3. itching postoperatively

    score yes/no

    Measured: one week

  4. problems with urinating postoperatively

    score yes/no

    Measured: one week

  5. Activity level postoperatively: return to normal

    score yes/no

    Measured: one week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jul 2020
  2. Study start1 Jul 2017
  3. Primary completion31 Dec 2018
  4. Study completion29 Feb 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
We will be using ropivacaine - naropin 7,5mg/ml, a local anaesthetic of the amide type. The administered dose of this local anaesthetic will be 3mg/kg for each patient. Depending on the study group the patient belongs to, this dose will be given in full by either local injection at the trocar entry points or by intraperitoneal injection or it will be divided between both injection sites
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04459026
Sponsor's protocol ID
ropivacaine
Status last verified
Jul 2020
First submitted
28 Feb 2018
Last updated
7 Jul 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing combination, infiltration and instillation in people with Postoperative Pain, run by Universiteit Antwerpen at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Abdominale Pain scores postoperatively (time frame: one week). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in